On Tuesday, Arrowhead Research Corp (NASDAQ:ARWR)’s shares inclined 4.20% to $7.44.
Arrowhead Research Corp (ARWR) declared that its Clinical Trial Application for ARC-520, its clinical candidate for chronic hepatitis B infection (HBV), has been approved by Germany’s Federal Institute for Drugs and Medical Devices. The company now has regulatory clearance in Germany for two additional Phase 2b multiple-dose studies of ARC-520 to be conducted in parallel. Arrowhead awaits final IRB approval from the sites, which are predictable shortly, and in addition, the company is engaged with regulatory authorities from Hong Kong and South Korea to open additional sites for these studies. Arrowhead will provide guidance in the future on timing for release of data from these studies.
The studies titled Heparc-2002 and Heparc-2003 will enroll patients with chronic HBV infection that are e-antigen (HBeAg) negative and HBeAg positive, respectively. Each study is a multicenter, randomized, double-blind, placebo-controlled, multi-dose study intended to evaluate two dose levels in parallel of ARC-520 in combination with entecavir or tenofovir in patients with immune active chronic HBV infection. The 2002 and 2003 studies are planned to enroll up to 60 and 90 patients, respectively. In each study, patients will be randomized to receive four doses, once every 4 weeks, of either 1 mg/kg ARC-520, 2 mg/kg ARC-520, or placebo at a ratio of 1:1:1.
Arrowhead Research Corporation develops novel drugs to treat intractable diseases in the United States. The company’s principal product candidates comprise ARC-520, an RNAi-based therapeutic that is in Phase IIa clinical trial to treat chronic hepatitis B virus infection; and ARC-AAT, a novel unlocked nucleobase analog containing RNAi-based therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. Its platform technology comprise Dynamic Polyconjugate platform, an RNAi delivery system that addresses multiple organ systems and cell types.
Mack Cali Realty Corp (NYSE:CLI)’s shares dropped -2.47% to $18.94.
Mack Cali Realty Corp (CLI) declared that Andrew Marshall has been promoted to the position of chief operating officer. In his new role, Mr. Marshall will oversee the day-to-day operations of Roseland and will continue as the Company’s executive vice president of development.
Mack-Cali Realty Corporation is a real estate investment trust (REIT). It engages in the leasing, administration, acquisition, development, and construction of commercial real estate properties in the United States. The firm invests in the real estate markets of the United States primarily in the northeastern United States, in addition to in the District of Columbia.
At the end of Tuesday’s trade, Iron Mountain Inc (NYSE:IRM)‘s shares dipped -0.64% to $32.57.
Iron Mountain® Incorporated (IRM), the storage and information administration company, recently declared the publishing of its 2014 Corporate Responsibility Report, providing a comprehensive update on the company’s global commitments to key Environmental, Social and Governance (ESG) topics such as workplace diversity and inclusion, community engagement, environmental responsibility, and employee volunteerism. Accessible for download on Iron Mountain’s Taking CARE corporate responsibility portal, the document expands on the company’s first report published last year.
Iron Mountain Incorporated, a real estate investment trust, provides storage and information administration services in North America, Europe, Latin America, and the Asia Pacific. It operates through North American Records and Information Administration Business, North American Data Administration Business, Western European Business, Other International Business, and Corporate and Other Business.
Xylem Inc (NYSE:XYL), ended its Tuesday’s trading session with 0.81% gain, and closed at $37.30.
Xylem Inc. (XYL), a leading global water technology company dedicated to solving the world’s most challenging water issues, congratulates Perry Alagappan of Houston, Texas, as the 2015 winner of the United States Stockholm Junior Water Prize (SJWP), the world’s most prestigious youth award for water-related science and technology projects.
Alagappan’s project, “Novel Renewable Filter for Heavy Metal Removal: A Practical Application of Functionalized Multi-Walled Carbon Nanotubes,” focused on developing an effective, renewable filter to remove toxic heavy metal contaminants that permeate our water supplies due to the proliferation of electronic waste. The project received the top honor out of the 50 state entries at the national competition held in Herndon, Virginia from June 19-20. In August, Alagappan will represent the United States at the International Stockholm Junior Water Prize competition in Stockholm, Sweden, where he will compete with 30 other students from around the world. Alagappan will also receive a $10,000 scholarship toward enhancing his water science education.
Xylem has been a sponsor of the Stockholm Junior Water Prize for the past 17 years and was a leading voice in its creation. Through its corporate citizenship and social investment program, Xylem Watermark, Xylem is working to build awareness and demand for science, technology, engineering and mathematics (STEM) education and careers, particularly in the field of water technology.
Xylem Inc. engages in the design, manufacture, and application of engineered technologies for the water and wastewater applications. The company operates in two segments, Water Infrastructure and Applied Water. The Water Infrastructure segment offers various products, counting water and wastewater pumps, treatment and testing equipment, and controls and systems, in addition to filtration, disinfection, and biological treatment equipment under the Flygt, WEDECO, Godwin, WTW, Sanitaire, YSI, and Leopold names for transportation, treatment, and testing of water and wastewater for public utilities and industrial applications.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
